Enhertu, a collaboration between AstraZeneca and Daiichi Sankyo, gains FDA approval for treating HER2-positive solid tumors spread throughout the body, marking a breakthrough in cancer treatment. It s the first antibody drug conjugate with such wide clearance, offering new hope for patients with limited treatment options. AstraZeneca anticipates further growth opportunities.